Acute myeloid leukemia in italian patients with multiple sclerosis treated with mitoxantrone

Neurology

Volumn 78, Issue 12, 2012, Pages 933-934

  Martinelli, Vittorio ^a   Straffi, Laura ^a   Comi, Giancarlo ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; DISEASE PREDISPOSITION; FOLLOW UP; HUMAN; INCIDENCE; ITALY; LETTER; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; ALGORITHM; CLINICAL PROTOCOL; ETHNIC DIFFERENCE; GENOTOXICITY; GERMANY; RISK ASSESSMENT; RISK FACTOR; CHEMICALLY INDUCED DISORDER; FEMALE; MALE; NOTE;

MITOXANTRONE; ANALGESIC AGENT;

ANALGESICS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MITOXANTRONE; MULTIPLE SCLEROSIS;

EID: 84860317152     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31824c46f5     Document Type: Note

References (6)

1. Martinelli V, Cocco E, Capra R, et al. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology 2011;77:1887-1895.
2. Stroet A, Starck M, Zettl U, et al. Incidence of therapyrelated acute leukemia in mitoxantrone-treated multiple sclerosis patients in Germany. Ther Adv Neurol Disord (in press 2012).
3. Le Page E, Leray E, Edan G. Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: A 5-year prospective study. Mult Scler 2011;17: 867-875.
4. Rivera V, Weinstock-Guttman B, Beagan J, Al-Sabbagh A, Bennett R, Dangond F. Final results from Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis Study (RENEW). Mult Scler 2009;15:S254.
5. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomized, multicenter trial. Lancet 2002;360:2018-2025. (Pubitemid 36026580)
6. Joannides M, Mays AN, Mistry AR, et al. Molecular pathogenesis of secondary acute promyelocytic leukemia. Mediterr J Hematol Infect Dis 2011;3: E2011045.